Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 2
2007 4
2008 8
2009 7
2010 2
2011 9
2012 6
2013 15
2014 13
2015 8
2016 7
2017 17
2018 11
2019 8
2020 4
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 32917784

102 results
Results by year
Filters applied: . Clear all
Page 1
A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD).
Toussaint ND, Pedagogos E, Lioufas NM, Elder GJ, Pascoe EM, Badve SV, Valks A, Block GA, Boudville N, Cameron JD, Campbell KL, Chen SSM, Faull RJ, Holt SG, Jackson D, Jardine MJ, Johnson DW, Kerr PG, Lau KK, Hooi LS, Narayan O, Perkovic V, Polkinghorne KR, Pollock CA, Reidlinger D, Robison L, Smith ER, Walker RJ, Wang AYM, Hawley CM; IMPROVE-CKD Trial Investigators. Toussaint ND, et al. J Am Soc Nephrol. 2020 Sep 11:ASN.2020040411. doi: 10.1681/ASN.2020040411. Online ahead of print. J Am Soc Nephrol. 2020. PMID: 32917784
Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
Ruospo M, Palmer SC, Natale P, Craig JC, Vecchio M, Elder GJ, Strippoli GF. Ruospo M, et al. Cochrane Database Syst Rev. 2018 Aug 22;8(8):CD006023. doi: 10.1002/14651858.CD006023.pub3. Cochrane Database Syst Rev. 2018. PMID: 30132304 Free PMC article.
Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study.
Lioufas N, Toussaint ND, Pedagogos E, Elder G, Badve SV, Pascoe E, Valks A, Hawley C; IMPROVE-CKD Writing Committee.. Lioufas N, et al. BMJ Open. 2019 Feb 21;9(2):e024382. doi: 10.1136/bmjopen-2018-024382. BMJ Open. 2019. PMID: 30796122 Free PMC article. Clinical Trial.
Aortic Calcification and Arterial Stiffness Burden in a Chronic Kidney Disease Cohort with High Cardiovascular Risk: Baseline Characteristics of the Impact of Phosphate Reduction On Vascular End-Points in Chronic Kidney Disease Trial.
Lioufas NM, Pedagogos E, Hawley CM, Pascoe EM, Elder GJ, Badve SV, Valks A, Toussaint ND; on behalf of the IMPROVE-CKD Investigators. Lioufas NM, et al. Am J Nephrol. 2020;51(3):201-215. doi: 10.1159/000505717. Epub 2020 Feb 5. Am J Nephrol. 2020. PMID: 32023606
Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.
Ix JH, Isakova T, Larive B, Raphael KL, Raj DS, Cheung AK, Sprague SM, Fried LF, Gassman JJ, Middleton JP, Flessner MF, Block GA, Wolf M. Ix JH, et al. J Am Soc Nephrol. 2019 Jun;30(6):1096-1108. doi: 10.1681/ASN.2018101058. Epub 2019 May 13. J Am Soc Nephrol. 2019. PMID: 31085679 Free PMC article. Clinical Trial.
Effects of phosphate binders in moderate CKD.
Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, Allison MA, Asplin J, Smits G, Hoofnagle AN, Kooienga L, Thadhani R, Mannstadt M, Wolf M, Chertow GM. Block GA, et al. J Am Soc Nephrol. 2012 Aug;23(8):1407-15. doi: 10.1681/ASN.2012030223. Epub 2012 Jul 19. J Am Soc Nephrol. 2012. PMID: 22822075 Free PMC article. Clinical Trial.
Vitamin K Supplementation to Improve Vascular Stiffness in CKD: The K4Kidneys Randomized Controlled Trial.
Witham MD, Lees JS, White M, Band M, Bell S, Chantler DJ, Ford I, Fulton RL, Kennedy G, Littleford RC, McCrea IV, McGlynn D, Panarelli M, Ralston MR, Rutherford E, Severn A, Thomson N, Traynor JP, Struthers AD, Wetherall K, Mark PB. Witham MD, et al. J Am Soc Nephrol. 2020 Aug 13:ASN.2020020225. doi: 10.1681/ASN.2020020225. Online ahead of print. J Am Soc Nephrol. 2020. PMID: 32817311
Progression of arterial stiffness is associated with changes in bone mineral markers in advanced CKD.
Krishnasamy R, Tan SJ, Hawley CM, Johnson DW, Stanton T, Lee K, Mudge DW, Campbell S, Elder GJ, Toussaint ND, Isbel NM. Krishnasamy R, et al. BMC Nephrol. 2017 Sep 4;18(1):281. doi: 10.1186/s12882-017-0705-4. BMC Nephrol. 2017. PMID: 28870151 Free PMC article. Clinical Trial.
Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD.
Liabeuf S, Ryckelynck JP, El Esper N, Ureña P, Combe C, Dussol B, Fouque D, Vanhille P, Frimat L, Thervet E, Mentaverri R, Prié D, Choukroun G; FRENCH Study collaborators. Liabeuf S, et al. Clin J Am Soc Nephrol. 2017 Dec 7;12(12):1930-1940. doi: 10.2215/CJN.03030317. Epub 2017 Oct 26. Clin J Am Soc Nephrol. 2017. PMID: 29074818 Free PMC article. Clinical Trial.
Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial.
Ureña-Torres P, Prié D, Keddad K, Preston P, Wilde P, Wan H, Copley JB. Ureña-Torres P, et al. BMC Nephrol. 2014 May 5;15:71. doi: 10.1186/1471-2369-15-71. BMC Nephrol. 2014. PMID: 24885942 Free PMC article. Clinical Trial.
102 results
Jump to page